Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1313733 | 0.89 | L3MBTL1 (0.74) | L3MBTL1ALDH1A1SMN1; SMN2HTTMAPT | |
| SCHEMBL6472886 | 0.86 | L3MBTL1 (0.59) | L3MBTL1TSHRALDH1A1SMN1; SMN2HTT | |
| SCHEMBL7239484 | 0.86 | L3MBTL1 (0.62) | L3MBTL1TSHRALDH1A1SMN1; SMN2HTT | |
| SCHEMBL6043936 | 0.85 | L3MBTL1 (0.58) | L3MBTL1TSHRALDH1A1SMN1; SMN2HTT | |
| SCHEMBL29173176 | 0.84 | L3MBTL1 (0.60) | L3MBTL1TSHRALDH1A1SMN1; SMN2HTT | |
| SCHEMBL27976581 | 0.83 | L3MBTL1 (0.56) | L3MBTL1TSHRALDH1A1SMN1; SMN2HTT | |
| SCHEMBL311206 | 0.83 | TDP1 (0.69) | L3MBTL1TSHRALDH1A1SMN1; SMN2HTT | |
| SCHEMBL25270406 | 0.82 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1SMN1; SMN2HTTMAPT | |
| SCHEMBL20831533 | 0.82 | TDP1 (0.72) | L3MBTL1TSHRALDH1A1HTTMAPK1 | |
| SCHEMBL31306844 | 0.82 | L3MBTL1 (0.54) | L3MBTL1TSHRALDH1A1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103889224-B | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC医疗公司 | 2017-05-24 | — | — | CN | disclosed |
| EP-2314295-B1 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | RESVERLOGIX INC (CA) | 2015-01-28 | — | — | EP | disclosed |
| US-20130281396-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| US-8410109-B2 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | RESVERLOGIX CORP. (CA) | 2013-04-02 | — | — | US | disclosed |
| US-8242130-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | disclosed |
| EP-1838296-B1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP (CA) | 2012-08-08 | — | — | EP | disclosed |
| US-8093273-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-01-10 | — | — | US | disclosed |
| EP-2332527-A2 | Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2011-06-15 | — | — | EP | disclosed |
| EP-2314295-A1 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | Resverlogix, Inc (CA) | 2011-04-27 | — | — | EP | disclosed |
| US-20090259048-A1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2009-10-15 | — | — | US | disclosed |
| US-20090029987-A1 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices | RESVERLOGIX CORP. (CA) | 2009-01-29 | — | — | US | disclosed |
| EP-1937069-A2 | HERBICIDAL COMPOSITIONS BASED ON 3-PHENYLURACILS AND N-[[4-[(CYCLOPROPYLAMINO)-CARBONYL]PHENYL]SULFONYL]-2-METHOXYBENZAMIDE | BASF SE (DE) | 2008-07-02 | — | — | EP | disclosed |
| EP-1909788-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES | RESVERLOGIX CORP. (CA) | 2008-04-16 | — | — | EP | disclosed |
| EP-1838296-A2 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2007-10-03 | — | — | EP | disclosed |
| WO-2007042447-A2 | HERBICIDAL COMPOSITIONS BASED ON 3-PHENYLURACILS AND N-[[4-[(CYCLOPROPYLAMINO)-CARBONYL]PHENYL]SULFONYL]-2-METHOXYBENZAMIDE | BASF SE (DE) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007016525-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES | RESVERLOGIX CORP. (CA) | 2007-02-08 | — | — | WO | disclosed |
| US-20060205767-A1 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | HEPALINK (HONG KONG) LIMITED (HK) | 2006-09-14 | — | — | US | disclosed |
| WO-2006045096-A2 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205767-A1 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | APOB, APOL1, FABP3 | L3MBTL1 3437/4885TSHR 4681/4885ALDH1A1 1211/4885 |
| US-20090259048-A1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, APOL1, FABP3 | L3MBTL1 3437/4885TSHR 4681/4885ALDH1A1 1211/4885 |
| US-20090029987-A1 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices | VCAM1, ICAM1, TGFB1 | L3MBTL1 4211/4885TSHR 4697/4885ALDH1A1 893/4885 |
| US-20130281396-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | BCOR, BMI1, PHKB | L3MBTL1 341/4885TSHR 4448/4885ALDH1A1 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.